Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Dr. Alessandro Fichera

Dr. Alessandro Fichera
Dr. Alessandro Fichera is a nationally renowned, board certified colorectal surgeon specializing in minimally invasive and robotic surgery for gastrointestinal cancers. In this video, Dr. Fichera discusses developing specific treatments for specific patients. Treatment of colorectal cancer has become more and more individualized. At SCCA we are able to identify the specific treatment for the specific patient. We no longer just use an approach that is used for everybody. We are becoming more advanced, specialized and complex in the way we treat colorectal cancer. At SCCA, researchers and clinicians work together on the same cases making clinical research part of our treatment procedure.

Related Videos

Colon Cancer Screening with Dr. Alessandro Fichera

Dr. Alessandro Fichera talks about prevention and early detection of colorectal cancer. Dr. Fichera is a surgeon and Director of Colorectal Surgical Oncology at the University of Washington and SCCA. Dr. Fichera stresses that colon and rectal cancer can be detected early and even prevented through routine colonoscopies. Pre-malignant stage polyps can be found and removed. Current low fiber and high fat diets increase many problems, including promoting colorectal cancers. Everyone should have a colonoscopy by the age of 50. First degree relatives of patients with colorectal cancer or polyps should have a colonoscopy by age 40. Earlier colonoscopies are recommended for individuals with a known mutation for familial polyposis, lynch syndrome, or other genetic predispositions.

Colon Cancer Treatment with Dr. Alessandro Fichera

Dr. Alessandro Fichera gives an overview of colon cancer. The majority of colon cancer cases develop from small polyps that become larger and then cancerous. Other pathways are being identified stemming from flat lesions or associated with inflammatory bowel disease, which are more difficult to detect. Regular colonoscopies are vital for early detection, and should occur by age 50 in the general population, or age 40 or earlier by those with a family history or genetic predisposition. The latest advances in treatment for colon cancer include the ability to see better with endoscopy, more effective medical and radiation treatments, and minimally invasive surgery being as effective as open surgery. The five-year cure rate for stage I cancers are 90%, and stage III as high as 70-75%. The key to success is working with a multidisciplinary team and getting the best treatment the first time.

Dr. Andrew Coveler

Dr. Andrew Coveler is a medical oncologist who treats cancers of the gastrointestinal system. In this video, Dr. Coveler discusses advances in gastrointestinal treatment at SCCA. ?Cancer treatments are good, but they?re not really good enough? says Dr. Coveler. This is what brought him to SCCA where he has become a gastrointestinal cancer specialist. That level of specialization made possible by SCCA can mean the difference between curable and not curable. We treat the some of the rarest forms of cancers from patients around the world. Over the last ten years, the introduction of new drugs like Herceptin, new surgical techniques and robotic surgery have dramatically improved gastrointestinal cancer survival rates. The team environment at Seattle Cancer Care Alliance brings all of the disciplines together to provide our patients with the best care in the world.

Dr. Edward Lin

Dr. Edward Lin is a medical oncologist who specializes in treating gastrointestinal cancers. In this video he describes how SCCA strives to better inform patients about their diagnosis and treatment plan, but more importantly, guide them on their treatment 1, 5, and even 10 years from now. This long-term relationship with patients shows just how successful SCCA is at treating cancer and our survival rate is of one of the best in the world. SCCA's physicians are heavily involved in the clinical trials and are constantly searching for new answers and new treatments for patients. Dr. Edward Lin also describes how SCCA is at the frontier of developing the next generation of gastrointestinal and cancer treatments.